ADMA Biologics Inc (NASDAQ:ADMA) Shares Bought by Picton Mahoney Asset Management

Key Points

• Picton Mahoney Asset Management significantly increased its stake in ADMA Biologics by approximately 207,037.5%, acquiring a total of 132,568 shares, which are valued at around $2.6 million.
• Several other institutional investors also modified their holdings in ADMA, with hedge funds now owning 75.68% of the company's stock, indicating strong institutional interest.
• ADMA Biologics reported a net margin of 45.01% and revenue of $114.8 million for the latest quarter, showing a 40.2% increase compared to the same quarter last year.

Picton Mahoney Asset Management lifted its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 207,037.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,568 shares of the biotechnology company's stock after purchasing an additional 132,504 shares during the period. Picton Mahoney Asset Management owned about 0.06% of ADMA Biologics worth $2,629,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in shares of ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares in the last quarter. New York State Teachers Retirement System grew its position in shares of ADMA Biologics by 96.2% in the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after purchasing an additional 108,800 shares in the last quarter. GAMMA Investing LLC grew its position in shares of ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock valued at $131,000 after purchasing an additional 4,715 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at approximately $201,000. Finally, Ameriprise Financial Inc. grew its position in shares of ADMA Biologics by 14.1% in the fourth quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock valued at $12,274,000 after purchasing an additional 88,542 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock worth $9,644,269 over the last ninety days. Corporate insiders own 3.50% of the company's stock.

ADMA Biologics Trading Up 3.4%

ADMA Biologics stock traded up $0.63 during mid-day trading on Friday, hitting $19.33. The company's stock had a trading volume of 2,469,666 shares, compared to its average volume of 2,296,092. The firm has a market capitalization of $4.61 billion, a PE ratio of 22.74 and a beta of 0.38. ADMA Biologics Inc has a 1 year low of $10.21 and a 1 year high of $25.67. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The stock's fifty day moving average is $18.81 and its two-hundred day moving average is $18.75.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the company earned $0.08 earnings per share. The firm's revenue for the quarter was up 40.2% on a year-over-year basis. On average, analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of analyst reports. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.